Investors Buy High Volume of Call Options on Pfizer (NYSE:PFE)

Key Points

• Pfizer call-option activity surged: Investors purchased 170,284 call options, about 47% above the typical volume, while the stock rose to $28.12 and traded near its 12-month high.
• Analyst sentiment remains cautious: Pfizer has an average “Hold” rating and a consensus price target of $28.28, despite several recent upgrades and downgrades. Institutional investors own 68.36% of the company.
• Pipeline progress is offset by patent-cliff concerns: Pfizer’s Lyme vaccine filing and early-stage obesity drug program advanced, while encouraging mRNA cancer-vaccine data supported sentiment. However, upcoming patent expirations could pressure future revenue and earnings.

Pfizer Inc. (NYSE:PFE - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock investors acquired 170,284 call options on the company. This represents an increase of approximately 47% compared to the typical volume of 115,735 call options.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PFE. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer in the fourth quarter valued at about $26,000. Keb Asset Management LLC bought a new stake in shares of Pfizer in the second quarter worth about $26,000. Field & Main Bank purchased a new position in Pfizer during the 2nd quarter valued at about $27,000. HFM Investment Advisors LLC raised its position in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 427 shares during the last quarter. Finally, Evolution Wealth Management Inc. lifted its holdings in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 566 shares during the period. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of analyst reports. BMO Capital Markets cut their price target on Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, July 13th. Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. JPMorgan Chase & Co. reduced their target price on Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a report on Wednesday, July 8th. Royal Bank Of Canada upgraded Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price target on the stock in a research report on Tuesday, June 9th. Finally, HSBC cut shares of Pfizer from a "buy" rating to a "hold" rating and lowered their target price for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, Pfizer has an average rating of "Hold" and a consensus target price of $28.28.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive cancer-vaccine read-through: Merck and Moderna reported an encouraging update from a clinical trial testing an mRNA-based cancer vaccine. Although Pfizer was not directly involved, the results lifted sentiment toward mRNA and next-generation cancer treatments—areas relevant to Pfizer’s oncology strategy and antibody-drug-conjugate intellectual property. Pfizer Stock Rallies Thanks to Merck and Moderna Cancer Trial Update
• Positive Sentiment: Lyme vaccine filing advances: The European Medicines Agency validated Pfizer and Valneva’s marketing application for their Lyme disease vaccine candidate, confirming that it is ready for full regulatory review. Late-stage data showed 73% efficacy and encouraging safety results, improving the potential for future product revenue, milestones, and royalties if approved. Pfizer Gets EMA Lyme Vaccine Filing Validation
• Positive Sentiment: Obesity pipeline progresses: Pfizer completed a Phase 1 study of experimental obesity drug PF-08653944. The program remains early-stage and carries substantial development risk, but progress could help Pfizer compete in the large obesity-treatment market. Pfizer Advances Early Obesity Drug
• Neutral Sentiment: Broad healthcare support: Healthcare indexes gained during Tuesday trading, providing a favorable backdrop for PFE and other pharmaceutical stocks. The sector-wide move may have contributed to Pfizer’s strength independently of company-specific news. Healthcare Stocks Climb Late Afternoon
• Negative Sentiment: Patent-cliff risk remains: Analysts continue to view Pfizer as attractively valued, but warn that upcoming patent expirations could pressure revenue and earnings as key products face generic or biosimilar competition. Pfizer Still Cheap Valuation Meets a Looming Patent Cliff

Pfizer Price Performance

PFE stock traded up $0.88 during mid-day trading on Wednesday, hitting $28.12. 36,926,558 shares of the stock were exchanged, compared to its average volume of 42,109,918. The business has a fifty day moving average price of $25.18 and a 200 day moving average price of $26.21. Pfizer has a 12 month low of $23.58 and a 12 month high of $28.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The stock has a market capitalization of $160.30 billion, a price-to-earnings ratio of 37.01 and a beta of 0.34.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same period last year, the firm posted $0.78 EPS. Pfizer's revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts anticipate that Pfizer will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.1%. Pfizer's payout ratio is presently 226.32%.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source